Why Dollar Tree Stock Is Rising Today

Dollar Tree, Inc. (NASDAQ: DLTR) shares are moving Wednesday after the company announced growth strategies, financial objectives, multi-year guidance and reaffirmed second-quarter and fiscal year 2023 guidance.

Dollar Tree, Inc. (NASDAQ:DLTR) shares are moving Wednesday after the company announced growth strategies, financial objectives, multi-year guidance and reaffirmed second-quarter and fiscal year 2023 guidance.

What To Know: Strategy and financial outlook will be discussed today at the company’s 2023 Investor Conference in Norfolk, Virginia.

Presentations by Chairman and CEO Rick Dreiling, CFO Jeff Davis, and members of the company’s executive management team will speak in detail about business segments, including growth strategies, financial objectives, multi-year outlook, and expectations of future cash available for capital allocation.

“Dollar Tree is on an exciting path of accelerating sales and profit. We have compelling plans in place to deliver expanded value assortment across multiple price points, enhance store standards for our customers, and add new technology and capabilities to accelerate progress with our supply chain and people development,” said Dreiling.

“As we pursue these initiatives, we are confident in our ability to achieve mid-single-digit comparable-store sales growth, gain market share, and expand our footprint. Achieving these results should drive substantial operating profit improvement across both banners, deliver EPS of $10 or more in fiscal year 2026, and produce significant available cash for shareholders.”

Second-quarter 2023 outlook is reaffirmed with consolidated net sales of $7.0 billion to $7.2 billion and diluted earnings per share of 79 cents to 89 cents.

Fiscal year 2023 outlook is reaffirmed with consolidated net sales of $30.0 billion to $30.5 billion and diluted earnings per share of $5.73 to $6.13.

Related Link: Why UniQure Stock Is Trading Down Today

DLTR Price Action: Shares of DLTR were up 4.46% at $142.63 at the time of publication, according to Benzinga Pro.

Image by Peggy Chai from Pixabay

 

Total
0
Shares
Related Posts
Read More

IMV Announced Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S; IMV Expects Its Current Cash Position Will Be Sufficient To Fund Operations Into The Second Half of 2023

IMV Inc. (Nasdaq: IMV; TSX: IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S). Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023

IMV